Gene · 3741
KCNA5: potassium voltage-gated channel subfamily A member 5
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. KCNA5: potassium voltage-gated channel subfamily A member 5. Genes, record 3741. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/3741
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P22460 | Potassium voltage-gated channel subfamily A member 5 | 613 | 0 | Ensembl, GeneID, HGNC |
Source UniProt
Patents24
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 58780 | P22460 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 1016 | P22460 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 2192 | P22460 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 2192 | P22460 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 1016 | P22460 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 65838 | P22460 | Espacenet |
| US 11400116 B2 | 2022-08-02 | 2590 | P22460 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 168809 | P22460 | Espacenet |
| US 11078247 B2 | 2021-08-03 | 5711 | P22460 | Espacenet |
| US 10753947 B2 | 2020-08-25 | 25 | P22460 | Espacenet |
1 to 10 of 24
See all 24 patentsDrugs9
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| AMIFAMPRIDINE | CHEMBL354077 | Voltage-gated potassium channel blocker | BLOCKER | ChEMBL |
| AMIFAMPRIDINE PHOSPHATE | CHEMBL3301611 | Voltage-gated potassium channel blocker | BLOCKER | ChEMBL |
| DALFAMPRIDINE | CHEMBL284348 | Voltage-gated potassium channel blocker | BLOCKER | ChEMBL |
| GUANIDINE | CHEMBL821 | Voltage-gated potassium channel blocker | BLOCKER | ChEMBL |
| GUANIDINE HYDROCHLORIDE | CHEMBL1200728 | Voltage-gated potassium channel blocker | BLOCKER | ChEMBL |
| NERISPIRDINE | CHEMBL2107762 | Voltage-gated potassium channel blocker | BLOCKER | ChEMBL |
| TEDISAMIL | CHEMBL113461 | Voltage-gated potassium channel blocker | BLOCKER | ChEMBL |
| VERNAKALANT | CHEMBL2111112 | Voltage-gated potassium channel subunit Kv1.5 blocker | BLOCKER | ChEMBL |
| VERNAKALANT HYDROCHLORIDE | CHEMBL2107383 | Voltage-gated potassium channel subunit Kv1.5 blocker | BLOCKER | ChEMBL |
Trials96
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07532460 | DALFAMPRIDINE | ClinicalTrials.gov | ||
| NCT07185347 | DALFAMPRIDINE | PHASE3 | ClinicalTrials.gov | |
| NCT07171203 | DALFAMPRIDINE | PHASE1 | ClinicalTrials.gov | |
| NCT06853015 | DALFAMPRIDINE | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT06751784 | DALFAMPRIDINE | PHASE2 | ClinicalTrials.gov | |
| NCT06596434 | DALFAMPRIDINE | PHASE2 | ClinicalTrials.gov | |
| NCT06333171 | DALFAMPRIDINE | PHASE2 | ClinicalTrials.gov | |
| NCT06294821 | DALFAMPRIDINE | PHASE2 | ClinicalTrials.gov | |
| NCT06136728 | DALFAMPRIDINE | PHASE3 | ClinicalTrials.gov | |
| NCT05919407 | AMIFAMPRIDINE | PHASE3 | ClinicalTrials.gov |
1 to 10 of 96
See all 96 trialsNIH grants1,163
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | KCNA5 papers | Newest fiscal year |
|---|---|---|---|
| R01HL131517 | Sex-specific arrhythmogenic mechanisms of atrial fibrillation | 8 | 2025 |
| R01HL092577 | IDENTIFICATION OF COMMON GENETIC VARIANTS FOR ATRIAL FIBRILLATION AND PR INTERVAL | 7 | 2025 |
| P01HL141084 | Multiscale Systems to Elucidate Susceptibility and Cardioprotective Mechanisms in Cardio-oncology | 5 | 2025 |
| P40OD010440 | Caenorhabditis Genetics Center | 4 | 2025 |
| T32HL086350 | Training Program in Basic and Translational Cardiovascular Science | 4 | 2025 |
| R01GM030376 | The Electrophysiological Studies of Voltage Gated Channels | 3 | 2025 |
| R01HL111600 | Sympathetic remodeling and ventricular arrhythmia | 3 | 2025 |
| R01HL141214 | Functional Microdomains in the Heart's Pacemaker: A New Dimension of Cardiac Remodeling | 3 | 2025 |
| R01HL142282 | CaMKII activation and regulation in adult cardiac myocytes | 3 | 2025 |
| T32DC000011 | Sensory Mechanisms and Disorders | 3 | 2025 |
1 to 10 of 1,163Source NIH's project files
See all 1,163 nih grantsPapers2,161
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Selective inhibition of LY294002 across cloned human cardiac ion channels: implications for atrium-selective therapy in atrial fibrillation. | Front Pharmacol | 2026 | 42780784 | PubTator, text mining | PubMed |
| Modulation of voltage-dependent K+ channel activity by the muscarinic receptor antagonist solifenacin in native coronary arterial smooth muscle cells. | Korean J Physiol Pharmacol | 2026 | 42733228 | PubTator, text mining | PubMed |
| Ion-Channel Activity of Characteristic Alkaloids From Uncaria rhynchophylla. | Chem Biodivers | 2026 | 42720106 | PubTator, text mining | PubMed |
| A designer pore-blocking peptide reveals an electrostatic complementation mechanism for the inhibition-resistant Kv1.5 channel. | Sci Adv | 2026 | 42696590 | PubTator, text mining | PubMed |
| Electrophysiological Characterization of MK886-Mediated Suppression of Voltage-Gated K+ Currents in Rabbit Coronary Artery Smooth Muscle Cells. | J Appl Toxicol | 2026 | 42487466 | PubTator, text mining | PubMed |
| The Genetics of Atrial Fibrillation: From Molecular Mechanisms to Precision Medicine. | Cureus | 2026 | 42371450 | PubTator, text mining | PubMed |
| Integrative network toxicology and single-cell analysis implicates a potential TGFBR1-centered fibroblast remodeling axis in Benzo[a]pyrene-related atrial fibrillation. | Environ Int | 2026 | 42364542 | PubTator, text mining | PubMed |
| Molecular-Genetic Basis of Pulmonary Arterial Hypertension (PAH). | Curr Issues Mol Biol | 2026 | 42353577 | PubTator, text mining | PubMed |
| The interplay between dynamic regulation of ion-channel gating and trafficking in cardiac arrhythmogenesis. | J Physiol | 2026 | 42330017 | PubTator, text mining | PubMed |
| Functional characterisation of KCNA5 gene variants linked to pulmonary arterial hypertension. | Eur Respir J | 2026 | 42315184 | PubTator, text mining | PubMed |
1 to 10 of 2,161
See all 2,161 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/3741
GET https://conductscience.org/api/genes/v1/3741/patents?page=2